-
Human Genome Sciences Offers 12.5 Million Common Shares
01 Dec 2009 10:14 GMT
… 1, 2009 (FinancialWire) — Human Genome Sciences, Inc. (NASDAQ: HGSI) has launched … ;p>
<p>Human Genome Sciences is a commercially focused biopharmaceutical … development, including ZALBIN for chronic hepatitis C and BENLYSTA for systemic …
-
Human Genome Sciences To Offer 18 Million Common Shares
28 Jul 2009 09:15 GMT
… , 2009 (FinancialWire) — Human Genome Sciences, Inc. (NASDAQ: HGSI) said it … p>Rockville, Maryland-based Human Genome Sciences is a commercially focused biopharmaceutical … , including Zalbin for chronic hepatitis C and Benlysta for systemic …
-
Gene Therapy, DNA's Past, RNA's Future: The Golden Era
02 Apr 2024 16:41 GMT
… therapy during the early 2000s. Human Genome Sciences built on the groundbreaking work … for treating diseases such as hepatitis C, lupus, anthrax, and cancer … of biotech companies such as Human Genome Sciences, Genzyme Corporation, Sangamo Therapeutics, and …
-
Want to Prevent Another Coronavirus Epidemic?
29 Jan 2020 21:28 GMT
… for the treatment of HIV, hepatitis B and herpes viruses. The … biological threats.” BioShield works. At Human Genome Sciences we developed the drug Abthrax …
-
AIDS Researcher Robert R. Redfield Named to Lead the C.D.C.
21 Mar 2018 22:01 GMT
… with H.I.V. and hepatitis C would help him “hit … underwriters have included Aventis, Gilead, Human Genome Sciences, Merck and Schering.
Kathleen Kennedy …
-
Biologics Market Trends and Forecasts to 2027
05 Dec 2017 15:03 GMT
… chronic disorders, including cancer, diabetes, hepatitis and autoimmune diseases such as …
Hexal
Hindustan Antibiotic
Histogenics
Hospira
Human Genome Sciences
Human Stem Cells Institute
Hypermarcas …